Archan Khandekar

Dr. Archan Khandekar

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JPJoao G. Porto
Joao G. Porto
MAMaria Camila Suarez Arbelaez
Maria Camila Suarez Arbelaez
BPBrandon Pena
Brandon Pena
AKArchan Khandekar
Archan Khandekar
AMAnkur Malpani
Ankur Malpani
HSHemendra N. Shah
Hemendra N. Shah
The microbiome, once considered peripheral, is emerging as a relevant player in the intricate web of factors contributing to cancer development and progression. These often overlooked microorganisms, in the context of urological malignancies, have been investigated primarily focusing on the gut microbiome, while exploration of urogenital microorganisms remains limited. Considering this, our systematic review delves into the complex role of these understudied actors in various neoplastic conditions, including prostate, bladder, kidney, penile, and testicular cancers. Our analysis found a total of 37 studies (prostate cancer 12, bladder cancer 20, kidney cancer 4, penile/testicular cancer 1), revealing distinct associations specific to each condition and hinting at potential therapeutic avenues and future biomarker discoveries. It becomes evident that further research is imperative to unravel the complexities of this domain and provide a more comprehensive understanding.

26 October 2024 in BJUI Compass
Verified
Journal Article
Open access
AKArchan Khandekar
Archan Khandekar
JPJoao G. Porto
Joao G. Porto
JDJean C. Daher
Jean C. Daher
PFPedro F. S. Freitas
Pedro F. S. Freitas
DADotan Asselman
Dotan Asselman
SPSanoj Punnen
Sanoj Punnen
Objectives: The objectives of this study are to compare the accuracy of warm ischemia times (WITs) derived by a surgical artificial intelligence (AI) software to those documented in surgeon operative reports during partial nephrectomy procedures and to assess the potential of this technology in evaluating postoperative renal function.Patients and methods: A surgical AI software (Theator Inc., Palo Alto, CA) was used to capture and analyse videos of partial nephrectomies performed between October 2023 and April 2024. The platform utilized computer vision algorithms to detect clamp placement and removal, enabling precise WIT measurement. Expert‐reviewed surgical videos served as the ground truth. Platform‐derived WITs were compared to those in surgeon operative reports using paired‐sample t‐tests. Additionally, we analysed the correlation between platform‐derived WITs and postoperative creatinine levels extracted from electronic health records (EHRs) integrated via health level seven (HL7) messaging protocols.Results: Of 64 eligible cases, 61 were included in the final analysis. Platform‐derived WITs were within 1 min of the ground truth in all procedures, within 30 s in 97%, and within 10 s in over 80%. The mean difference between platform‐derived WITs and ground truth was 8.3 s, significantly lower than the 2.45 min difference for operative reports (p < 0.001). No significant correlation was found between platform‐derived WIT and postoperative creatinine changes, aligning with the view that WIT may not independently determine postoperative renal function. Although not the primary goal of this study, significant correlations were observed between WIT, tumour size and RENAL score.Conclusion: This study demonstrates the high accuracy of a surgical intelligence platform in measuring WIT during partial nephrectomies. The findings support the use of AI‐based surgical time measurement for precise intraoperative documentation and highlight the potential of integrating these data with EHRs to advance research on surgical outcomes.

18 September 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
JPJoao G. Porto
Joao G. Porto
MSMaria Camila Suarez
Maria Camila Suarez
BPBrandon Peña
Brandon Peña
AKArchan Khandekar
Archan Khandekar
AMAnkur Malpani
Ankur Malpani
HSHemendra N. Shah
Hemendra N. Shah
The microbiome, once considered peripheral, is emerging as a relevant player in the intricate web of factors contributing to cancer development and progression. These often overlooked microorganisms, in the context of urological malignancies, have been investigated primarily focusing on the gut microbiome, while exploration of urogenital microorganisms remains limited. In light of this, our systematic review delves into the complex role of these understudied actors in various neoplastic conditions, including prostate, bladder, kidney, penile, and testicular cancers. Our analysis found a total of 37 studies, with prostate cancer-12, bladder cancer-20, kidney cancer-4, penile/testicular cancer-1, which reveals distinct associations specific to each condition, hinting at potential therapeutic avenues and future biomarker discoveries. It becomes evident that further research is imperative to unravel the complexities of this domain and provide a more comprehensive understanding.

18 May 2026 in BJUI Compass
Verified
Journal Article
Open access
GSGurpremjit Singh
Gurpremjit Singh
AKArchan Khandekar
Archan Khandekar
AAAhmad Abdelaziz
Ahmad Abdelaziz
HSHemendra N. Shah
Hemendra N. Shah
SPSanoj Punnen
Sanoj Punnen
DPDipen J. Parekh
Dipen J. Parekh
Objective: To develop and validate machine learning models for predicting 30‐day major morbidity and mortality in patients undergoing radical cystectomy (RC) using the American College of Surgeons National Surgical Quality Improvement Project (ACS‐NSQIP) and to compare performance against a logistic regression model. Material and methods: We identified 11 241 patients from the ACS‐NSQIP database 2020–2024 who underwent radical cystectomy. Demographics and comorbidities were extracted along with targeted variables from the NSQIP RC‐targeted database. The cohort was split into a training and an independent validation dataset. Predictive models were developed for logistic regression, random forest (RF) and XGBoost. Model performance was evaluated using the area under the receiver operating characteristic (ROC) curve, SHapley Additive exPlanations (SHAP) analysis, sensitivity, specificity and Brier scores. Results: Of 11 241 patients, 2691 (23.9%) experienced at least one major complication, and 185 (1.6%) died within 30 days. Overall complications were 6365 (56.62%). Non‐survivors were significantly older (72.65 ± 10.14 vs. 68.50 ± 10.32 years, p < 0.001). Patients with major morbidity had lower mean albumin levels (3.92 ± 0.56 vs. 4.01 ± 0.48, p < 0.001). Logistic regression identified high BMI (OR 1.15, p < 0.001), black race (OR 1.34, p = 0.003), Hispanic ethnicity (OR 1.37, p = 0.009), prior pelvic surgery (OR 1.15, p = 0.002) and continent diversions (OR 1.46, p = 0.001) as predictors of 30‐day major morbidity, while low frailty (mFI‐5 ≤ 1; OR 0.72, p = 0.001) and higher preoperative albumin (OR 0.88, p < 0.001) were protective. For 30‐day mortality, increasing age (OR 1.42, p < 0.001) was the strongest risk factor. For 30‐day morbidity, the XGBoost model achieved the highest AUC 0.796 (95% CI: 0.783–0.814). For 30‐day mortality, the RF model showed superior discrimination with an AUC of 0.921 (95% CI: 0.908–0.934). SHAP analysis showed predictors of major morbidity were frailty, BMI and advanced age, whereas predictors of mortality were age, ASA class and preoperative creatinine levels. Decision curve analysis showed net clinical benefit for all three models. The web‐based tool can be accessed and used for prediction ( https://cystectomyai.streamlit.app/ ). Conclusions: We developed and validated machine learning models for 30‐day major morbidity and 30‐day mortality following radical cystectomy. These findings support the integration of machine learning into clinical workflows to enhance preoperative counselling and personalized risk reduction.

27 February 2026 in BJU International
Verified
Journal Article
Open access
AMAnkur Malpani
Ankur Malpani
JRJonathan T. Ryan
Jonathan T. Ryan
HYHui Yu
Hui Yu
NSNachiketh Soodana‐Prakash
Nachiketh Soodana‐Prakash
AKArchan Khandekar
Archan Khandekar
SPSanoj Punnen
Sanoj Punnen
Objectives: To evaluate basal‐luminal cell of origin subtyping using Prediction Analysis of Microarray of 50 genes (PAM50) genomic classification profiles for predicting disease progression in men undergoing active surveillance (AS) for prostate cancer (PCa). Patients and Methods: In the prospective Miami Active Surveillance Trial (MAST) trial, 205 men undergoing AS received serial multiparametric magnetic resonance imaging (MRI) and biopsies, including MRI‐targeted and systematic sampling. The highest‐grade core from each biopsy was sent for expression profiling using Decipher, a clinical‐grade transcriptome assay (Veracyte Inc., San Diego, CA, USA). Basal‐luminal subtyping was evaluated using PAM50 molecular subtype models. PCa grade progression was compared across subtypes, as were gene mutation signatures, prognostic indices, and pathway activities. Kaplan–Meier curves, log‐rank test, and multivariable Cox regression were used to assess association between PAM50 and grade progression. Heatmaps and volcano plots were rendered to illustrate potential mechanistical differences between PAM50 subtypes. Results: Of the 205 patients, 128 had transcriptome data for baseline basal‐luminal classification. PAM50 identified 46 Luminal A (LA), 26 Luminal B (LB), and 56 Basal subtypes. Decipher scores were lowest in LA, followed by Basal, and highest in LB. Grade progression‐free survival was worse in patients with the LB subtype (median 1.7 years) compared to those with LA and Basal subtypes (median 2.9 years; log‐rank P = 0.005); LB patients had grade progression‐free survival of 34% by 24 months of AS, compared to 63% for Basal or 68% for LA. Transcriptome analysis showed distinct enrichment profiles for each subtype, with LB strongly associated with SPOP and CHD1 mutations. Limitations include small sample size and single‐institution setting. Conclusion: The PAM50 basal‐luminal subtyping shows promise as a molecular classification tool for predicting progression risk in PCa. This is one of the only prospective studies evaluating PAM50 subtyping for predicting cancer progression in a cohort of men undergoing AS for PCa.

1 January 2025 in Healthcare Technology Letters
Verified
Journal Article
Open access
AKArchan Khandekar
Archan Khandekar
ASAryan Shah
Aryan Shah
LELuis Esparza
Luis Esparza
FBFrida Toscano Bello
Frida Toscano Bello
BLBruno Liebl
Bruno Liebl
DPDipen J. Parekh
Dipen J. Parekh
Introduction: Augmented reality (AR) is seeing an increase in its applications in healthcare, but its reach in outpatient care remains undefined. Patients in outpatient settings face poor medical understanding. AR may help address this gap between patients and physicians through immersive and interactive models and supporting tools. This narrative review aims to evaluate the status of AR in outpatient care, categorise its applications, and identify limitations and future research needs. Methods: Four databases–PubMed, Embase, Web of Science and Cochrane Library–were conducted for peer‐reviewed studies published from January 2015 to February 2025. Studies were included if they regarded AR interventions in outpatient care settings. Studies were analysed and grouped thematically into five clinical domains of AR intervention. Results: After review, 19 studies–spanning 987 participants–were included. AR applications were categorised into patient education and engagement (n = 3), cognitive and functional assessment (n = 3), device interaction and remote monitoring (n = 3), procedural guidance in outpatient interventions (n = 5), and rehabilitation and functional recovery support (n = 5). Most included studies were pilot studies (n = 6) and had relatively small sample sizes (median = 28). Studies proved that AR interventions consistently improved patient understanding, engagement and procedural support. Nevertheless, studies faced limitations including the need for specialised and bulky hardware–which affected patient comfort as well–reliability issues, technical difficulties and platform‐specific inconsistencies. Conclusion: AR has been proved to have the potential to improve outpatient care across five main areas: patient education, cognitive and functional assessment, medical device interaction, procedural guidance and rehabilitation. Studies consistently support that AR enhances patient comprehension, engagement and procedural accuracy while allowing for remote monitoring and personalised therapy. Furthermore, AR interventions demonstrate high usability and clinical relevance. Nevertheless, limitations such as hardware complexity and inconsistent technical performance remain. Future research should prioritise large‐scale RCTs and strategies to integrate AR into pre‐existing digital workflows.